openPR Logo
Press release

Relapsing Refractory Multiple Myeloma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Allogene, Anaveon, Arcellx, Cartesian Therapeutics, Cellectis, Gilead, I-MAB Biopharma, Ichnos, iTeos

08-24-2023 05:19 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Relapsing Refractory Multiple Myeloma Pipeline Assessment

Las Vega (Nevada), United States //- As per DelveInsight's assessment, about 55+ key pharma and biotech companies are working on 60+ pipeline drugs in the Relapsing Refractory Multiple Myeloma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Relapsing Refractory Multiple Myeloma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Relapsing Refractory Multiple Myeloma Therapeutics Market.

The report provides a detailed description of the Relapsing Refractory Multiple Myeloma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Relapsing Refractory Multiple Myeloma Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Relapsing Refractory Multiple Myeloma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Relapsing Refractory Multiple Myeloma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing Refractory Multiple Myeloma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Relapsing Refractory Multiple Myeloma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Relapsing Refractory Multiple Myeloma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Relapsing Refractory Multiple Myeloma Therapeutics Domain:
https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Relapsing Refractory Multiple Myeloma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Relapsing Refractory Multiple Myeloma Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Latest Key Update in the Relapsing Refractory Multiple Myeloma Therapeutics Market
On April 04, 2023, Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in the company's ongoing CaMMouflage Phase 1 clinical trial in patients with r/r MM.

The Leading Companies in the Relapsing Refractory Multiple Myeloma Therapeutics Market Include:
Allogene Therapeutics, Anaveon AG, Arcellx, Array Biopharma, Bristol-Myers Squibb, Cartesian Therapeutics, Cellectis, Gilead Sciences, Harpoon Therapeutics, Heidelberg Pharma AG, Hrain Biotechnology Co., Ltd., I-MAB Biopharma, Ichnos Sciences, iTeos Therapeutics, Luminary Therapeutics, Novartis, ONK Therapeutics, Oricell Therapeutics, Pfizer, Poseida Therapeutics, Regeneron Pharmaceuticals, Seagen Inc., Sorrento Therapeutics, Takeda, TeneoOne, Trillium Therapeutics Inc., Virtuoso BINco, Inc., Xencor, and others.

Relapsing Refractory Multiple Myeloma Emerging and Marketed Drugs Covered in the Report Include:
• Mezigdomide: Bristol-Myers Squibb
• Iopofosine: Cellectar Biosciences, Inc.
• ORIC-533: ORIC Pharmaceuticals
• Isatuximab: Sanofi
• JNJ-68284528: Legend Biotech Biotech/Janssen Biotech
• GSK2857916: GlaxoSmithKline
• Ibrutinib: Pharmacyclics
• Xpovio: Karyopharm Therapeutics
• bb2121/bb21217: Celgene
• Melflufen: Oncopeptides
• JNJ-68284528: Janssen Research & Development
• P-BCMA-101 CAR-T cells: Poseida Therapeutics
• Anti-BCMA CAR-T: CARsgen
And Many More

Get an in-depth Assessment of the Emerging Therapies and Relapsing Refractory Multiple Myeloma Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Relapsing Refractory Multiple Myeloma Current Treatment Patterns
4. Relapsing Refractory Multiple Myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsing Refractory Multiple Myeloma Late-Stage Products (Phase-III)
7. Relapsing Refractory Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsing Refractory Multiple Myeloma Discontinued Products
13. Relapsing Refractory Multiple Myeloma Product Profiles
14. Relapsing Refractory Multiple Myeloma Companies
15. Relapsing Refractory Multiple Myeloma Drugs
16. Dormant and Discontinued Products
17. Relapsing Refractory Multiple Myeloma Unmet Needs
18. Relapsing Refractory Multiple Myeloma Future Perspectives
19. Relapsing Refractory Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Healthcare Consulting and Competitive Intelligence Services by DelveInsight
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market

Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

Antibody-Mediated Graft Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-graft-rejection-market

Bacterial (Pyogenic) Meningitis Market
https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market

Bevacizumab Biosimilars
https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight

Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market

Calcinosis Cutis Market
https://www.delveinsight.com/report-store/calcinosis-cutis-market

Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market

Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market

Epstein Barr virus (EBV) Market
https://www.delveinsight.com/report-store/epstein-barr-virus-ebv-market

Glabellar Frown Lines Market
https://www.delveinsight.com/report-store/glabellar-frown-lines-market

Goitre Market
https://www.delveinsight.com/report-store/goitre-market

Hereditary Deafness Medical Device Market
https://www.delveinsight.com/report-store/hereditary-deafness-medical-devices-market

ICOS-Next Generation Immunotherapy Market
https://www.delveinsight.com/report-store/icos-next-generation-immunotherapy-competitive-landscape

Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market

Peripherally Inserted Central Catheter (PICC) Devices Market
https://www.delveinsight.com/report-store/peripherally-inserted-central-catheter-picc-devices-market

Severe Toxicities in Lymphoma Market
https://www.delveinsight.com/report-store/severe-toxicities-in-lymphoma

Single Ventricle Heart Disease Market
https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market

Small Fiber Neuropathy Market
https://www.delveinsight.com/report-store/small-fiber-neuropathy-market

Stuttering Market
https://www.delveinsight.com/report-store/stuttering-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Hyperopia Market
https://www.delveinsight.com/report-store/hyperopia-market

Microvascular Angina Market
https://www.delveinsight.com/report-store/microvascular-angina-market

Progressive Familial Intrahepatic Cholestasis Market
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market

CRISPR Therapies Pipeline Insight
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight

Endometrial Hyperplasia Market
https://www.delveinsight.com/report-store/endometrial-hyperplasia-market

Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market

Chronic Pain Associated with Painful Diabetic Neuropathy Market
https://www.delveinsight.com/report-store/chronic-pain-associated-with-painful-diabetic-neuropathy-market

Contact Dermatitis Market
https://www.delveinsight.com/report-store/contact-dermatitis-market

Dermal Mycosis Market
https://www.delveinsight.com/report-store/dermal-mycosis-market

High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

Lymphatic Malformations Market
https://www.delveinsight.com/report-store/lymphatic-malformations-market

Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market

Ulcer Haemorrhage Market
https://www.delveinsight.com/report-store/ulcer-haemorrhage-market

Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market

Alcohol Use Disorder (AUD) Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market

Cell And Gene Therapy For Multiple Myeloma Market
https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market

Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

End-Stage Coronary Artery Disease Market
https://www.delveinsight.com/report-store/end-stage-coronary-artery-disease-market

Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market

Cell and Gene Therapies in Rare Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market

Glycogen Storage Disease Market
https://www.delveinsight.com/report-store/glycogen-storage-disease-market

Maple Syrup Urine Disease Market
https://www.delveinsight.com/report-store/maple-syrup-urine-disease-market

MELAS Syndrome Market
https://www.delveinsight.com/report-store/melas-syndrome-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Relapsing Refractory Multiple Myeloma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Allogene, Anaveon, Arcellx, Cartesian Therapeutics, Cellectis, Gilead, I-MAB Biopharma, Ichnos, iTeos here

News-ID: 3180568 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Multiple

Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386 Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983 This latest report researches the industry structure,
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)